What is Immatics N.V.'s Shariah compliance score?

Immatics N.V.'s (IMTX) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Immatics N.V. pass AAOIFI screening?

Immatics N.V. (IMTX) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (IMTX: 1.2%), (3) interest-bearing deposits below 30% (IMTX: 36.1%), and (4) prohibited income below 5% (IMTX: 35.6%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Immatics N.V. stock?

Immatics N.V. (IMTX) has a non-permissible income ratio of 35.59%. Muslim investors should purify this percentage of any dividends received and capital gains realized from IMTX shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Immatics N.V. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Immatics N.V. (IMTX) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about IMTX's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

IMTX: Is Immatics N.V. Halal?

Immatics N.V.

NASDAQHealthcareDE

$9.68

-2.81%

Market Cap: 1.3B

Compliance Status

Not Halal

Screened on Jul 19, 2026 · AAOIFI Standard 21

Non-Compliant

0Score

Is Immatics N.V. (IMTX) halal? Not Halal. Based on AAOIFI screening, Immatics N.V. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

1.2% of 30.0% limit

What this means for you

Most scholars advise not holding IMTX

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About Immatics N.V.

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 19, 2026

Compliance History

Not Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: FMP

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.45

-0.02%

0002.KLA+

Kotra Industries Bhd

$3.72

+0.01%

0075.KLA+

LYC Healthcare Bhd

$0.01

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.47

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.29

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track IMTX and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Immatics N.V. (IMTX) halal to invest in?

Immatics N.V. (IMTX) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Immatics N.V. get a F compliance rating?

Immatics N.V. (IMTX) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 1.2% (limit 30%); interest-bearing deposits of 36.1% (limit 30%); prohibited income of 35.59% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Immatics N.V.'s Shariah verdict?

Immatics N.V.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Immatics N.V. re-screened for Shariah compliance?

Immatics N.V. (IMTX) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 19, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.